Both BATMAN (feasibility) and POWERSTORE (scale-up) directly target high-energy-density batteries using metallic lithium anodes, showing sustained R&D commitment to this chemistry.
MIKROMASCH EESTI OU
Estonian SME developing high-energy lithium metal anode batteries for renewable microgeneration, with full SME Instrument Phase 1–2 track record.
Their core work
MikroMasch is an Estonian technology SME developing next-generation lithium metal anode batteries for energy storage, with a specific focus on applications in renewable energy microgeneration. Their work spans from early-stage feasibility research into novel battery chemistries through to product-level scale-up, targeting the gap between small-scale renewable generation and affordable, high-energy-density storage. They brought a product to market readiness using the EU SME Instrument pathway — first validating the concept, then securing a substantial Phase 2 grant to commercialize it. Their background in precision micro-manufacturing (the company's core heritage) likely informs their approach to battery electrode fabrication.
What they specialise in
POWERSTORE explicitly targets storage solutions for renewables microgeneration, positioning battery technology within distributed clean energy systems.
Successfully navigated the full SME Instrument pathway (Phase 1 feasibility → Phase 2 scale-up), demonstrating capability to translate research into market-ready products.
The company name and heritage suggest micro-fabrication expertise that likely underpins their battery electrode development work in both projects.
How they've shifted over time
MikroMasch's H2020 trajectory follows a clean product development arc: they entered with a feasibility study (BATMAN, 2015) to validate a metallic lithium anode battery concept, then scaled directly into a funded commercialization phase (POWERSTORE, 2017). This is not a research drift — it is a deliberate technology development pipeline. The keyword data is sparse, but the project titles and funding scheme progression (SME-1 → SME-2) confirm a consistent, deepening focus on battery energy storage rather than a pivot to new domains.
MikroMasch was on a commercialization trajectory with their battery technology as of 2019 — any future collaboration would likely engage a company in late-stage product development or post-market industrial partnership, not early research.
How they like to work
MikroMasch operated exclusively as a solo SME Instrument beneficiary — both projects were self-led with no recorded consortium partners, which is typical for this funding scheme. They are not a consortium-builder; they are a focused product company that used EU funding as a direct R&D investment tool. Working with them would mean engaging as a customer, investor, or technology licensee rather than as a traditional research consortium partner.
MikroMasch has no recorded H2020 consortium partners — both projects were executed under the solo-applicant SME Instrument scheme. Their collaborative network within EU-funded research is effectively zero, making them a standalone technology developer rather than a networked research actor.
What sets them apart
MikroMasch is one of very few Estonian SMEs to complete the full SME Instrument Phase 1 to Phase 2 pipeline in the energy storage space, receiving over €1.3M to scale a proprietary battery technology. Their differentiation is the combination of micro-fabrication heritage with advanced battery chemistry — a manufacturing-grounded approach to a problem most players tackle from a pure chemistry angle. For anyone looking for a Baltic region deep-tech energy storage company with a commercialization track record, they are a rare find.
Highlights from their portfolio
- POWERSTOREThe largest grant in their portfolio (€1.29M via SME Phase 2), this project represents a full commercial scale-up of their proprietary battery technology for renewable microgeneration — the clearest signal of product readiness.
- BATMANA successful SME Phase 1 feasibility study that directly unlocked POWERSTORE, demonstrating a disciplined R&D-to-market pipeline rather than one-off project opportunism.